Compare Amgen, Inc. (AMGN) vs D R Horton Inc (DHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs D R Horton Inc — how do they compare? Amgen, Inc. trades at $359.29 (market cap $196.12B), while D R Horton Inc trades at $152.26 (market cap $42.98B). The key difference: Amgen, Inc. is far larger — about 4.6× D R Horton Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | DHI | |
|---|---|---|
Market Cap | $196.12B | $42.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $184.04 |
52-Week Low | $271.18 | $129.82 |
Enterprise Value | $241.41B | $47.70B |
Dividend Yield | 2.77% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
D.R. Horton (DHI) trades at $151.58, up 1.36% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with declining revenue ($34.25B in 2025) and net income margins (9.51%), though valuation metrics remain reasonable (P/E 14.23). Analyst consensus leans neutral with a $163.13 price target, while cash flow trends show volatility with a $1.51B net outflow in 2025.
The housing market headwinds and cyclical nature of homebuilding present near-term risks, but DHI's scale and operational efficiency offer stability. With the stock trading below consensus targets and showing technical support at $145, value-oriented investors may find opportunity amid sector challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
